In this research, glucose was adopted as the switching layer of resistive random access memory (RRAM) for transient electronics. The fabricated glucose-based RRAM showed bipolar switching behavior with stable endurance (100 cycles) and retention (10⁴ seconds) characteristics, without significant degradation, demonstrating its stable data storage capability and reliability. To investigate the switching mechanism of the glucose-based RRAM, various organic materials were prepared for the switching layer of RRAM. In addition, the dissolution characteristic of the glucose-based RRAM was evaluated to investigate the feasibility of its utilization for transient electronics, using a water-soluble substrate: a sodium carboxymethyl cellulose film. With this approach, a biocompatible glucose-based RRAM was successfully fabricated for future transient electronics.

Anaplastic thyroid cancer (ATC) is an undifferentiated and advanced form of thyroid cancer, accompanied with a high ratio of epigenetic adjustment, which occurs more than genetic mutations. In this study, we aimed to evaluate the synergistic anticancer effect (in vitro and in vivo) of the new combination of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and sorafenib with radiation therapy in pre-clinical models of ATC. The ATC cell lines, YUMC-A1 and YUMC-A2, were isolated from the current patients who were treated with HNHA and sorafenib, either as monotherapy or combination therapy. Synergistic anticancer effect of the combination therapy on the intracellular signaling pathways and cell cycle was assessed via flow cytometry and immunoblot analysis. To examine tumor shrinkage activity in vivo, an ATC cell line-derived mouse xenograft model was used. Results showed that the combination therapy of HNHA and sorafenib with radiation promoted tumor suppression via caspase cleavage and cell cycle arrest in patient-derived ATC. In addition, the combination therapy of HNHA and sorafenib with radiation was more effective against ATC than therapy with HNHA or sorafenib with radiation. Thus, the combination of HNHA and sorafenib with radiation may be used as a novel curative approach for the treatment of ATC.

Kim HJ, et al. J Endocr Surg. 2020 Dec;20(4):97-102. https://doi.org/10.16956/jes.2020.20.4.97

Post-extubastion respiratory symptoms (PERS) are a common sequelae of endotracheal intubation, impeding postoperative recovery. Despite the widespread use of prophylactic corticosteroids and symptomatic management, these approaches have limitations in alleviating PERS. In this study, we aim to evaluate the efficacy and safety of nasal herbal steam therapy (NHST), a traditional Korean medicine intervention, in managing PERS among patients with thyroid cancer following endotracheal intubation. In this pragmatic, parallel-group randomized controlled trial, 66 post-thyroidectomy patients with thyroid cancer who underwent endotracheal intubation will be randomly assigned in a 1:1 ratio to either the NHST group or the standard care group. The intervention group will receive personalized NHST for 5 consecutive days, whereas the control group will follow conventional postoperative care protocols. The primary endpoint is the change in Wisconsin Upper Respiratory Symptom Survey scores from baseline to day 5. Secondary endpoints included patient-reported symptom relief, safety assessments, and adherence rates. By investigating the therapeutic potential of NHST, this study will establish its role as a non-invasive, adjunctive intervention for improving intubation-related complications, potentially contributing to broadening integrative treatment strategies and optimizing recovery outcomes for patients with PERS. The study will be conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of CHA Ilsan Medical Center (ICHA 2024-011-006, date of approval 2024-09-04).

Kim NK, et al. J Endocr Surg. 2025 Jun;25(2):66-77. https://doi.org/10.16956/jes.2025.25.2.66

Objectives: This study aimed to develop a clinical pathway (CP) for post-operative care in patients with thyroid cancer in integrative medical center setting, specifically targeting the improvement of quality of life (QoL) and clinical management standardization. The CP was refined through a modified Delphi method and subsequently monitored in a clinical setting.Methods: The CP model was based on an analysis of medical records of thyroid cancer patients from July 2022 to February 2024. A time-task matrix was established, categorizing tasks by timeline (pre-operative, operation day, post-operative) and clinical activities (KM (Korean Medicine) evaluation, treatment, activity, diet, education). The draft CP model was validated using the modified Delphi method. Finally, the CP was pilot-tested in a clinical environment monitoring indicators such as CP application rate, completion rate, QoL, and satisfaction levels. To evaluate the CP, THYCA-QoL questionnaire was used, and pain levels were assessed using the Numeric Rating Scale (NRS).Results: The final CP model showed 81.8% application rate and 100% completion rate during the monitoring period. Results of THYCA-QoL questionnaire showed significant improvement in various aspects, including neuromuscula, oral and throat, and psychological issues. The NRS indicated a 48.1% reduction in neck pain intensity after post-CP application. Both patient and medical staff satisfaction increased following the CP's applicationConclusions: The integrative CP model for post-operative care in thyroid cancer patients improved QoL and reduced pain, demonstrating its potential as a standardized tool of integrative cancer healthcare settings. Future studies should refine the model and expand its use to validate efficacy and optimize quality of care.